Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
about
Neurofilament light chain predicts disease activity in relapsing-remitting MS.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression.Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome.Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
P2860
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Plasma neurofilament light cha ...... table therapies to fingolimod.
@en
Plasma neurofilament light cha ...... table therapies to fingolimod.
@nl
type
label
Plasma neurofilament light cha ...... table therapies to fingolimod.
@en
Plasma neurofilament light cha ...... table therapies to fingolimod.
@nl
prefLabel
Plasma neurofilament light cha ...... table therapies to fingolimod.
@en
Plasma neurofilament light cha ...... table therapies to fingolimod.
@nl
P2093
P2860
P50
P356
P1476
Plasma neurofilament light cha ...... table therapies to fingolimod.
@en
P2093
Fredrik Piehl
Tomas Olsson
P2860
P304
1352458517715132
P356
10.1177/1352458517715132
P577
2017-06-01T00:00:00Z